Return to Genitourinary Cancer Specialty Channel

Genitourinary Cancer Newswatch

The FDA granted accelerated approval to sacituzumab govitecan to treat adult patients with locally advanced or metastatic urothelial cancer (mUC), who have previously received a platinum-containing…
Data from a community-based cohort study of patients with NMIBC suggest that 1- and 5-year high-risk recurrences and progression increase with higher tumor classification and grade at diagnosis.
Ipilimumab plus nivolumab yielded anti-tumor activity with acceptable toxicity in patients with metastatic RCC previously given immune checkpoint inhibitors.
Pembrolizumab was active in patients with advanced or metastatic cisplatin-ineligible urothelial carcinoma, according to long-term study findings.
The FDA approved avelumab for the first-line maintenance treatment of patients with locally advanced metastatic or urothelial carcinoma who have not progressed on first-line platinum-containing…
The FDA has approved olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic HRR gene-mutated mCRPC that progressed following prior therapy.
Switch maintenance pembrolizumab led to improved PFS and ORRs in patients with metastatic urothelial cancer, according to results from a phase 2 study.
Findings from a large retrospective study suggest that teratoma is not a prognostic factor in patients with metastatic testicular germ cell tumors.
Stay in the know.
OncNet Newsletter